Cryo-Cell

OverviewSuggest Edit

Cryo-Cell International is a provider of cord blood banking and cord tissue storage services. The company is organized in three reportable segments: cellular processing and cryogenic cellular storage, with a current focus on the collection and preservation of umbilical cord blood stem cells for family use; the manufacture of PrepaCyte CB Processing System units, the processing technology used to process umbilical cord blood stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use.

TypePublic
Founded1989
HQOldsmar, FL, USMap
Websitecryo-cell.com
Employee Ratings3.4More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Nov 2019)87(-5%)
Revenue (FY, 2020)$31.1 M(-2%)
Share Price (Jun 2021)$8.3(-6%)
Cybersecurity ratingBMore

Key People/Management at Cryo-Cell

David I. Portnoy

David I. Portnoy

Co-CEO, Chairman
Mark L. Portnoy

Mark L. Portnoy

Co-CEO
Julie Allickson

Julie Allickson

VP Laboratory Operations and R&D
Oleg Mikulinsky

Oleg Mikulinsky

CIO
Todd Schuesler

Todd Schuesler

Director of Laboratory Operations
Show more

Cryo-Cell Office Locations

Cryo-Cell has offices in Oldsmar, North Miami Beach, Las Condes, San Pedro Sula and in 3 other locations
Oldsmar, FL, US (HQ)
700 Brooker Creek Blvd #1800
North Miami Beach, FL, US
15807 Biscayne Blvd #203
Las Condes, CL
Los Militares 5620, oficina 1213
San Pedro Sula, HN
6 Calle S
Guadalajara, MX
Av Aztecas 295
Metrobús, PA
Av Balboa
Show all (7)

Cryo-Cell Financials and Metrics

Cryo-Cell Revenue

Embed Graph
View revenue for all periods
Cryo-Cell's revenue was reported to be $31.15 m in FY, 2020
USD

Revenue (FY, 2020)

31.1m

Gross profit (FY, 2020)

21.5m

Gross profit margin (FY, 2020), %

69%

Net income (FY, 2020)

3.6m

EBIT (FY, 2020)

7.7m

Market capitalization (11-Jun-2021)

66.2m

Closing stock price (11-Jun-2021)

8.3

Cash (30-Nov-2020)

10.4m

EV

63.0m
Cryo-Cell's current market capitalization is $66.2 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

23.1m25.4m29.2m31.8m31.1m

Revenue growth, %

10%10%15%9%

Cost of goods sold

5.8m6.7m8.5m10.0m9.7m

Gross profit

17.4m18.7m20.7m21.8m21.5m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

5.8m6.2m6.9m6.2m6.5m7.9m7.5m8.1m8.2m7.6m7.9m8.1m

Cost of goods sold

1.5m1.6m2.0m1.6m1.8m2.5m2.5m2.6m2.6m2.5m2.5m2.4m

Gross profit

4.3m4.6m4.9m4.6m4.7m5.4m5.0m5.5m5.6m5.1m5.4m5.8m

Gross profit Margin, %

74%74%71%74%73%68%67%68%69%67%68%71%
show all
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

3.5m6.3m6.0m6.5m10.4m

Accounts Receivable

4.1m5.1m5.9m6.1m6.3m

Prepaid Expenses

395.5k372.2k461.8k500.3k611.6k

Inventories

361.1k314.6k16.0m1.1m927.3k
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

3.5m4.7m4.7m7.0m6.5m7.0m7.1m6.5m7.3m8.4m8.4m8.1m

Accounts Receivable

4.4m4.6m4.9m4.9m4.8m5.5m5.7m5.8m5.9m5.8m6.0m6.5m

Prepaid Expenses

460.0k498.7k406.1k298.1k488.8k597.0k460.6k61.6k526.3k451.7k684.9k599.4k

Inventories

286.0k296.3k335.8k374.4k424.5k16.2m16.1m1.0m1.0m1.1m1.1m1.2m
show all
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(1.3m)2.3m(854.8k)2.3m3.6m

Depreciation and Amortization

286.7k230.0k317.3k401.3k372.3k

Inventories

114.5k46.6k316.7k(27.4k)454.9k

Accounts Payable

329.6k443.1k(666.9k)107.5k(411.7k)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

486.9k983.9k1.6m(2.5m)(2.0m)(1.7m)275.9k329.6k1.4m687.0k1.6m2.4m

Depreciation and Amortization

57.6k113.7k171.7k60.3k120.3k214.3k104.9k208.3k304.5k95.8k190.9k284.7k

Inventories

75.2k64.9k25.4k(59.9k)(109.9k)182.5k(96.7k)10.9k25.3k70.4k293.8k237.7k

Accounts Payable

34.7k(300.4k)(122.2k)(730.6k)(815.4k)(808.8k)(251.3k)(232.7k)(248.6k)12.1k(417.3k)(469.2k)
show all
USDFY, 2016

Revenue/Employee

345.2k

Debt/Equity

-0.6 x

Debt/Assets

0.5 x

Financial Leverage

-1.3 x
Show all financial metrics

Cryo-Cell Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Cord Blood and Cord Tissue Specimen Stored

300 k450 k500 k500 k

Manufacturing Facilities, sq. ft.

18 k18 k18 k18 k
Show all operating metrics

Cryo-Cell Acquisitions / Subsidiaries

Company NameDateDeal Size
Cord:Use Cord Blood Bank, IncJune 04, 2018$14 m

Cryo-Cell Revenue Breakdown

Embed Graph

Cryo-Cell revenue breakdown by business segment: 97.4% from Umbilical Cord Blood and Cord Tissue Stem Cell Service and 2.6% from Other

Cryo-Cell Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

Learn more about our premium products
SecurityScorecard logo

Cryo-Cell Online and Social Media Presence

Cryo-Cell's Trends

Embed Graph

Cryo-Cell Company Culture

  • CEO Rating

    C

    70/100

Learn more on Comparably

Cryo-Cell News and Updates

May 10, 2021

Cryo-Cell International Proudly Announces Two Ongoing COVID-19 Related Trials

MIAMI, May 10, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell’s Medical Director, Dr. Joanne Kurtzberg and her research team at The Marcus Center for Cellular Cures (MC3) at Duke University School of Medicine are currently conducting two major studies: MASC (Phase 1/2) & MISTIC (Phase 1) to treat, respect…
April 14, 2021

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2021 Financial Results

OLDSMAR, Fla., April 14, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2021.
February 26, 2021

Cord Blood Banking Leader Cryo-Cell International Enters Into An Exclusive License Agreement with Duke University

MIAMI, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells, has entered into a collaborative license agreement with Duke University. The agreement grants Cryo-Cell the rights to proprietary proce…
October 15, 2020

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2020 Financial Results

OLDSMAR, Fla., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2020.
July 10, 2020

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2020 Financial Results

OLDSMAR, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2020. 

Cryo-Cell Blogs

March 10, 2020

How Are Coronavirus, Pregnancy, & Cord Blood Banking Linked?

With the sudden outbreak of coronavirus, pregnant women have become concerned about how COVID-19 will affect them. As the race to find a fast and effective treatment option continues, many are seeking a solution in cellular therapy. Research in the clinical trial setting is pointing to the fact tha…
February 18, 2020

Is There Potential for Cord Blood NK Cells to Treat Cancer and Coronavirus?

Among the different types of stem cells that cord blood contains, natural killer (NK) cells exhibit unique properties capable of targeting cancer cells and virus-infected cells. With the sudden outbreak of viruses such as 2019-nCoV, otherwise known as coronavirus, there becomes an even greater need…
January 24, 2020

Cord Blood and Cord Tissue Research: A Decade in Retrospect

In the spirit of retrospection, as we have entered a new decade, we wanted to pay homage to the advancements this past decade has seen in regards to cord blood and cord tissue research. The past ten years have yielded a tremendous amount of research in what is possible in the way of regenerative tr…
December 10, 2019

Cord Blood Saved My Son's Life: A Mother's Perspective

Mary Webb was joined by her children, Quentin (16) and Jory (11), to speak at Cryo-Cell's Cord Blood Educator Conference this year. At the age of four, Quentin was diagnosed with acute lymphoblastic leukemia (ALL). She shared her impactful story of dealing with her son’s cancer diagnosis and how, n…
November 26, 2019

2019 World Cord Blood Day Highlights

November 15th was World Cord Blood Day (WCBD), a day organized and hosted by Save the Cord Foundation to promote awareness and education on the topic of cord blood. The day’s presentations centered around the research and incredible life-saving potential of cord blood stem cells. Several great spea…
November 06, 2019

An Impactful Message from Dr. Kurtzberg: Cord Blood Transplant Stories

This past October, Cryo-Cell’s passionate team of cord blood educators met with Dr. Joanne Kurtzberg, from Duke University Medical Center, to hear about the latest developments in clinical trials using cord blood and cord tissue. Her presentation was centered around recent advancements, and she als…
Show more

 Cryo-Cell Frequently Asked Questions

  • When was Cryo-Cell founded?

    Cryo-Cell was founded in 1989.

  • Who are Cryo-Cell key executives?

    Cryo-Cell's key executives are David I. Portnoy, Mark L. Portnoy and Julie Allickson.

  • How many employees does Cryo-Cell have?

    Cryo-Cell has 87 employees.

  • What is Cryo-Cell revenue?

    Latest Cryo-Cell annual revenue is $31.1 m.

  • What is Cryo-Cell revenue per employee?

    Latest Cryo-Cell revenue per employee is $358 k.

  • Who are Cryo-Cell competitors?

    Competitors of Cryo-Cell include Americord, Igenomix and GATC Biotech.

  • Where is Cryo-Cell headquarters?

    Cryo-Cell headquarters is located at 700 Brooker Creek Blvd #1800, Oldsmar.

  • Where are Cryo-Cell offices?

    Cryo-Cell has offices in Oldsmar, North Miami Beach, Las Condes, San Pedro Sula and in 3 other locations.

  • How many offices does Cryo-Cell have?

    Cryo-Cell has 7 offices.